Literature DB >> 1370766

Effect of tolmetin sodium dihydrate on adhesion formation by intraperitoneal administration of antineoplastic agents.

K E Rodgers1, W Girgis, G S diZerega.   

Abstract

Antineoplastic agents are currently being administered through catheters placed intraperitoneally to treat cancer localized to the peritoneum. This route allows for high local concentrations of antineoplastic drug at the tumor site with low levels of the drug systemically, thereby reducing the systemic toxicity. However, there are complications with this mode of delivery, including a decrease in catheter patency and induction of adhesion formation, which leads to decreased drug dispersion and limits continuing drug administration. A model was developed in rats to mimic this method of antineoplastic drug administration that produced fibrin deposition around the catheter and adhesion formation involving bowel, intestines and liver. All antineoplastic agents tested, including Adriamycin, methotrexate, bleomycin, mitoxantrone and cisplatin, induced moderate to severe adhesion formation with varying effects on catheter patency. When an intraperitoneal bolus of tometin encapsulated in liposomes was tested with Adriamycin delivered via an osmotic minipump, a reduction in adhesion formation was observed. However, highly significant adhesion reduction was found when tolmetin was coadministered with the antitumor agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370766     DOI: 10.1007/bf00686260

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  9 in total

1.  Inhibition of postsurgical adhesions by liposomes containing nonsteroidal antiinflammatory drugs.

Authors:  K Rodgers; W Girgis; G S diZerega; K Bracken; L Richer
Journal:  Int J Fertil       Date:  1990 Sep-Oct

2.  Intraperitoneal chemotherapy for advanced ovarian cancer.

Authors:  W E Lucas; M Markman; S B Howell
Journal:  Am J Obstet Gynecol       Date:  1985-06-15       Impact factor: 8.661

Review 3.  The use of intraperitoneal chemotherapy in the treatment of ovarian cancer.

Authors:  C Myers
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

4.  Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer.

Authors:  N F Hacker; J S Berek; R G Pretorius; J Zuckerman; S Eisenkop; L D Lagasse
Journal:  Obstet Gynecol       Date:  1987-11       Impact factor: 7.661

5.  Chemotherapy for murine ovarian cancer: a rationale for ip therapy with adriamycin.

Authors:  R F Ozols; G Y Locker; J H Doroshow; K R Grotzinger; C E Myers; R I Fisher; R C Young
Journal:  Cancer Treat Rep       Date:  1979-02

6.  Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.

Authors:  E S Casper; D P Kelsen; N W Alcock; J L Lewis
Journal:  Cancer Treat Rep       Date:  1983-03

7.  Effects of tolmetin sodium dihydrate on normal and postsurgical peritoneal cell function.

Authors:  K Rodgers; D Ellefson; W Girgis; L Scott; G S diZerega
Journal:  Int J Immunopharmacol       Date:  1988

8.  High-dose intracavitary cisplatin with intravenous thiosulfate. Low incidence of serious neurotoxicity.

Authors:  M Markman; S Cleary; C E Pfeifle; S B Howell
Journal:  Cancer       Date:  1985-11-15       Impact factor: 6.860

9.  Intraperitoneal cisplatin with systemic thiosulfate protection.

Authors:  S B Howell; C L Pfeifle; W E Wung; R A Olshen; W E Lucas; J L Yon; M Green
Journal:  Ann Intern Med       Date:  1982-12       Impact factor: 25.391

  9 in total
  1 in total

1.  Preoperative intraperitoneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications.

Authors:  W Adachi; S Koike; M Rafique; S Kajikawa; G Kaneko; T Kuroda; F Iida; K Ishii
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.